Asparaginate

Base Information

• Chemical Name: Asparaginate
• CAS No.: 9015-68-3
• Molecular Formula: Unspecified
• Molecular Weight: 295.35
• Hs Code.: 3507909090
• European Community (EC) Number: 232-765-3
• Wikidata: Q27115042
• NCI Thesaurus Code: C286
• RXCUI: 1156
• Mol file: 9015-68-3.mol

Synonyms:Asparaginase;Asparaginase II;Asparaginase medac;Asparagine Deaminase;Colaspase;Crasnitin;Deaminase, Asparagine;Elspar;Erwinase;Kidrolase;Leunase;medac, Asparaginase;Paronal

Chemical Property of Asparaginate

Chemical Property:

• Appearance/Colour: white powder
• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: 2-8°C
• XLogP3: -2.8
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 2
• Exact Mass: 131.04566709
• Heavy Atom Count: 9
• Complexity: 128

Purity/Quality:

97.7% ^*data from raw suppliers

L-Asparaginase ^*data from reagent suppliers

Safty Information:

• Pictogram(s): 61-42/43-63:
• Hazard Codes: T,Xn
• Statements: 61-42/43-63
• Safety Statements: 53-22-36/37/39-45-36/37

MSDS Files:

Total 1 MSDS from other Authors

Useful:

• Drug Classes: Antineoplastic Agents
• Canonical SMILES: C(C(C(=O)[O-])N)C(=O)N
• Recent ClinicalTrials: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
• Recent EU Clinical Trials: Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric
• Description: Asparaginase is a kind of enzyme that can be used as a medication and in food industry. It is mainly extracted from E. coli. In the medical field, it can be used for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, and non-Hodgkin’s lymphoma. This is due to that asparaginase can convert the L-asparagine into aspartate and ammonia, exhausting the available asparagine needed for leukemic cells and thus leading to cell death. In the food industry, it can be used as a processing aid in the manufacture of food to reduce the formation of acrylamide, which is a potential carcinogen through removing the asparagine which can undergo Maillard reaction during cooking to induce tumor in fried and baked food. Using the enzyme asparaginase (L-asparagine amidohydrolase, EC 3.5.1.1), it is possible to significantly reduce the formation of the cooking carcinogen acrylamide during roasting, deep-frying, or baking of foods. The enzyme hydrolyzes free asparagine to aspartic acid, thereby preventing the formation of acrylamide by reaction of asparagine with reducing sugars at elevated temperatures during the Maillard reaction. The mitigation of acrylamide formation is especially important for a number of cereal- and potato-based products, including crackers, crispbread, gingerbread, biscuits, French fries, and potato chips. After asparaginase pretreatment, the acrylamide concentration of certain foods could be reduced by up to 97 % [84, 86]. By means of in vitro directed evolution, the properties of asparaginase were optimized. For example, an Asp133Leu mutation of a wild-type enzyme showed a significantly improved thermal stability. The enzyme’s half-life at 50 C increased from 3 to 160 h, and the half-inactivation temperature of the mutant was 9 C higher.
• Uses: Antineoplastic. Asparaginase from Escherichia coli has been used: to compare the cytotoxic effect of L-asparaginase purified from?Streptomyces brollosae?NEAE-115as a standard in asparaginase assay to quantify asparaginase activities in various eel tissuesto elicit amino acid deprivation
• Indications: The enzyme L-asparaginase (Elspar) is derived from the bacteria Escherichia coli and Erwinia carotovora. It catalyzes the hydrolysis of L-asparagine to aspartic acid and ammonia. L-Glutamine also can undergo hydrolysis by this enzyme, and during therapy, the plasma levels of both amino acid substrates fall to zero.Tumor cells sensitive to L-asparaginase are deficient in the enzyme asparagine synthetase and therefore cannot synthesize asparagine. Depletion of exogenous asparagine and glutamine inhibits protein synthesis in cells lacking asparagine synthetase, which leads to inhibition of nucleic acid synthesis and cell death.
• Therapeutic Function: Antineoplastic (acute leukemia)
• Clinical Use: The major indication for L-asparaginase is in the treatment of acute lymphoblastic leukemia; complete remission rates of 50 to 60% are possible. Lack of crossresistance and bone marrow toxicity make the enzyme particularly useful in combination chemotherapy. LAsparaginase also can be used in the treatment of certain types of lymphoma. It has no role in the treatment of nonlymphocytic leukemias or other types of cancer. Pegaspargase, a polyethylene glycol conjugate of L-asparaglnase (ASNase), was launched for combination chemotherapy in acute lymphoblastic leukemia (ALL). L-Asparaginase is an enzyme that inhibits protein synthesis by the depletion of sources of L-asparagine, which is necessary for transformed lymphoid cells to proliferate. It has been used as a standard component of the antileukemia armamentarium for childhood All. Pegaspargase has greater antitumor activity, a longer plasma half-life and less immunogenicity than ASNase. It produces minimal side effects after repeated dosing, whereas ASNase induces anaphylactic shock, urticaria, anorexia or vomiting and acute pancreatitis in dogs, and other immunological effects in man resulting from sensitization to the enzyme or protein synthesis inhibition. The efficacy of pegaspargase for other indications including breast and lung cancers, non-Hodgkin's lymphoma and pancreatic cancer has been reported.